BeiGene, Ltd.
BGNE
株式のランク
#1193
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
株価
$184.00
最終同期: 2025-01-02
時価総額
$19.28B
変化（1日）
-0.38%
変化（1年）
0.00%
国
US
取引 BeiGene, Ltd. (BGNE)
カテゴリー
Healthcare
BeiGene, Ltd.（BGNE）の利益
Jun 2026 時点の利益 TTM: $868.08M
BeiGene, Ltd. の最新の財務報告によると、同社の現在の利益は $868.08M です。2023 年には $-825.84M の利益を上げ、これは 2022 年の利益 $-1.96B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
BeiGene, Ltd. の利益の推移（2013 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $868.08M | -262.87% |
| 2024 | $-533.00M | -35.46% |
| 2023 | $-825.84M | -57.89% |
| 2022 | $-1.96B | 36.32% |
| 2021 | $-1.44B | -11.10% |
| 2020 | $-1.62B | 71.49% |
| 2019 | $-943.59M | 36.79% |
| 2018 | $-689.83M | 657.52% |
| 2017 | $-91.06M | -23.58% |
| 2016 | $-119.16M | 108.68% |
| 2015 | $-57.10M | 207.89% |
| 2014 | $-18.55M | 134.94% |
| 2013 | $-7.89M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 507.65% |
US
|
|
| $-3.09B | -455.61% |
US
|
|
| $-4.02B | -562.65% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 124.71% |
NL
|
